MedTrace Logo

Description of the Ability to Learn How to Handle Inhaler Devices in COPD

NCT02813200 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-14

No results posted yet for this study

Summary

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the world and further increase in its prevalence and mortality has been predicted. Currently, the main long-term treatments are the long-acting beta-2 agonist, indacaterol, salmeterol and the anticholinergic drug, tiotropium and glycopyrronium, used alone or in combination:

* long-acting beta-2 agonist with corticosteroid (e.g. salmeterol/fluticasone),
* long-acting beta-2 agonist with anticholinergic (e.g. indacatetrol/glycopyrronium).

These drugs are delivered to the lung using different inhaler devices such as Breezhaler ®, Handihaler® and Diskus®.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Seretide® Diskus® 500/550 μg

Every day during 7 days

DRUG

Ultibro® Breezhaler® 110/50 μg

Every day during 7 days

DRUG

Spiriva® Respimat® 2,5 μg

Every day during 7 days

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Hélène PEYROUZET, Dr · Service Hospitalo-Universitaire de Pharmacologie Médicale

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2019-02-28
Completion
2019-03-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02813200 on ClinicalTrials.gov